Jiangsu HengRui Medicine Co., Ltd.: Carcinoma trials
The registry lists 18 Carcinoma studies with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor. 2 are open to participants now and 3 have results posted.
Phase 1 5Phase 2 10Phase 3 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial CarcinomaRecruitingNCT06639347Phase 1/2
- Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT05444088Phase 1/2
- SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.CompletedNCT03558191Phase 2Results posted
- A Study to Evaluate SHR-1210 in Subjects With Advanced HCCCompletedNCT02989922Phase 2Results posted
- Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)CompletedNCT02329860Phase 3Results posted
- SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT05020925Phase 1/2
- A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)TerminatedNCT04985136Phase 3
- Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 NegativeActive, not recruitingNCT04842617Phase 3
- SHR-1701 in Patients With Recurrent/Metastatic ScchnStatus unknownNCT04650633Phase 2
- SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04282070Phase 1
- Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological TumorsStatus unknownNCT03827837Phase 2
- Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT03707509Phase 3
- A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.Status unknownNCT03605706Phase 3
- A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLCCompletedNCT03134872Phase 3
- A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLCStatus unknownNCT03085069Phase 2
- Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal CarcinomaCompletedNCT01462474Phase 1
- Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)CompletedNCT01392235Phase 2
- A Study of Apatinib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT01192971Phase 2